| Diabetic Microvascular Complications |
1 |
1 |
| Biologic Therapy |
0 |
0.86 |
| Orbit |
0 |
0.65 |
| Angiogenesis Inhibitors |
0 |
0.58 |
| Humanized Monoclonal Antibody |
0 |
0.58 |
| Retinal Diseases |
0 |
0.45 |
| Diabetic Macular Edema |
0 |
0.99 |
| Care and Maintenance of Vision |
0 |
0.35 |
| Macular Edema |
0 |
0.33 |
| Edema |
0 |
0.23 |
| Medical Life |
0 |
0.16 |
| Visual Acuity |
0 |
0.15 |
| Revenue and Practice Management |
0 |
0.14 |
| Grant |
0 |
0.12 |
| Match |
0 |
0.12 |
| Type 2 Diabetes Mellitus |
0 |
0.11 |
| Diabetic Retinopathy |
0 |
0.08 |
| Retina |
0 |
0.08 |
| Travel Medicine |
0 |
0.08 |
| Health Insurance |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.05 |
| Refractive Error |
0 |
0.05 |
| Biomedical Technology |
0 |
0.04 |
| Blindness |
0 |
0.04 |
| Epidemiology |
0 |
0.04 |
| Financial Reimbursement |
0 |
0.04 |
| Insurance |
0 |
0.04 |
| Medicare |
0 |
0.04 |
| Michigan |
0 |
0.04 |
| Patient Counseling |
0 |
0.04 |
| Retinopathy |
0 |
0.04 |
| Shared Decision-Making |
0 |
0.04 |
| Snellen Chart |
0 |
0.04 |
| Texas |
0 |
0.04 |